Zacks Investment Research Downgrades Basilea Pharmaceutica (OTCMKTS:BPMUF) to Hold

Basilea Pharmaceutica (OTCMKTS:BPMUF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks.com reports.

According to Zacks, “Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. “

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Basilea Pharmaceutica in a research note on Wednesday, August 18th.

Shares of OTCMKTS:BPMUF opened at $46.00 on Thursday. The company has a market cap of $494.04 million, a PE ratio of -30.07 and a beta of 1.38. Basilea Pharmaceutica has a twelve month low of $45.05 and a twelve month high of $61.00. The company’s 50 day moving average is $46.00 and its 200 day moving average is $48.11.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include Cresemba, Zevtera, Derazantinib, BAL101553, and BAL3833. The company was founded on October 17, 2000 and is headquartered in Basel, Switzerland.

Featured Article: What are the components of an earnings report?

Get a free copy of the Zacks research report on Basilea Pharmaceutica (BPMUF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.